atorvastatin has been researched along with HIV Coinfection in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.27) | 18.2507 |
| 2000's | 14 (31.82) | 29.6817 |
| 2010's | 20 (45.45) | 24.3611 |
| 2020's | 9 (20.45) | 2.80 |
| Authors | Studies |
|---|---|
| Di Santo, R | 1 |
| Alkaabi, M; Amoodi, AA; Baraka, MA; Don, J; Elnour, AA; Farah, FH; Mazrouei, NA; Ramadan, A; Sadeq, A; Sam, KG | 1 |
| Aberg, JA; Aweeka, F; Bosch, RJ; Brates, I; Deitchman, A; Nixon, D; Rahman, F | 1 |
| Baker, JV; Gorelick, RJ; Krishnan, S; Laidlaw, E; Lisco, A; Manion, M; Migueles, SA; Mystakelis, HA; Poole, A; Rupert, A; Sereti, I; Welker, JL; Wilson, E | 1 |
| Aman Nasution, S; Estiasari, R; Jasirwan, COM; Purnamasari, D; Rusdi, L; Shinta Noviar, M; Syahrir Azizi, M; Wulandari, EAT; Yunihastuti, E | 1 |
| Jimenez, VC; Norris, KA; Outwater, JA; Rabacal, W; Rayens, E; Schweitzer, F; Tarantelli, R; Whang, P | 1 |
| Battegay, M; Cavassini, M; Courlet, P; Decosterd, L; Marzolini, C; Saldanha, SA; Stader, F; Stoeckle, M | 1 |
| Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Guidi, M; Marzolini, C; Stader, F; Stoeckle, M | 1 |
| Blanco, J; Bonjoch, A; Clotet, B; Echeverría, P; Jiménez, M; Loste, C; Negredo, E; Pérez-Álvarez, N; Puig, J; Urrea, V | 1 |
| Giraldo-Giraldo, C; Machado-Alba, JE; Medina-Morales, DA; Valladales-Restrepo, LF | 1 |
| Araújo, PSR; Godoi, ET; Lacerda, HR; Leite, KME; Santos Junior, GGD; Vasconcelos, AF | 1 |
| Christenson, R; deFilippi, C; Grinspoon, SK; Grundberg, I; Lee, H; Lo, J; Stone, L; Zanni, MV | 1 |
| Christenson, R; deFilippi, C; Fitch, KV; Grinspoon, SK; Hoffmann, U; Joyce, J; Lo, J; Looby, SE; Lu, MT; Park, EA; Wu, A | 1 |
| Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Desfontaine, V; Marzolini, C; Spaggiari, D | 1 |
| Brown, E; Crane, HM; Delaney, JA; Eron, JJ; Hunt, PW; Kahn, JO; Kitahata, MM; Liu, W; Mathews, WC; Mugavero, MJ; Muñoz, MA; Napravnik, S; Saag, MS; Willig, JH | 1 |
| Also, MA; Bastida, C; Letang, E; Miró, JM; Pericas, JM; Tuset, M | 1 |
| Bayigga, L; Elliott, A; Joloba, M; Kaleebu, P; Kambugu, AD; Kamya, MR; Kiragga, A; Mayanja-Kizza, H; Nabatanzi, R; Nakanjako, D; Sekaly, R; Ssinabulya, I | 1 |
| Bansal, A; Burkholder, G; Goepfert, PA; Kahan, SM; Overton, ET; Sterrett, S; Westfall, AO; Zajac, AJ | 1 |
| Freiberg, MS; Justice, A; Lo Re, V | 1 |
| Abbara, S; Fitch, KV; Grinspoon, SK; Hoffmann, U; Hwang, J; Ihenachor, EJ; Lo, J; Looby, SE; Lu, MT; Oh, J; Plutzky, J; Robbins, G; Tawakol, A; Wei, J; Zimmerman, CO | 1 |
| Fitch, KV; Grinspoon, SK; Hoffmann, U; Kim, EA; Lee, H; Lo, J; Looby, SE; Lu, MT; Nou, E | 1 |
| Eckard, AR; Longenecker, CT; McComsey, GA | 1 |
| Ballocca, F; Barbero, U; Biondi-Zoccai, G; Bonora, S; Calcagno, A; Cannillo, M; Cerrato, E; D'Ascenzo, F; DiNicolantonio, JJ; Gaita, F; Gasparini, M; Gili, S; Grosso Marra, W; Lavie, CJ; Lonni, E; Mancone, M; Montefusco, A; Moretti, C; Omedè, P; Pianelli, M | 1 |
| Sungkanuparph, S; Wangpatharawanit, P | 1 |
| Aaron, L; Abzug, MJ; Anthony, P; Best, BM; Borkowsky, W; Borum, PR; Crain, MJ; Graham, B; Melvin, AJ; Meyer, WA; Montepiedra, G; Shin, K; Siberry, GK; Spiegel, HM | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Contadini, I; Magistrelli, E; Re, MC; Viale, P | 1 |
| Critchfield, J; Deeks, SG; Lee, E; Lollo, N; Price, RW; Probasco, JC; Spudich, SS | 1 |
| Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pavoni, M; Pocaterra, D | 1 |
| Crane, HM; Crane, PK; Harrington, RD; Kitahata, MM; Knopp, RH; Kosel, BW; Mugavero, MJ; Saag, MS; Singh, S; Willig, JH | 1 |
| Bavaro, M; Brandt, C; Crum-Cianflone, N; Decker, CF; Follmann, D; Ganesan, A; Higgins, J; Maldarelli, F; Metcalf, J; Qin, J; Rehm, C; Sklar, P; Tasker, S; Vita, J | 1 |
| Clumeck, N; De Wit, S; Delforge, M; Necsoi, CV | 1 |
| González, M; González-Santos, P; Márquez, M; Palacios, R; Ruiz, J; Santos, J; Valdivielso, P | 1 |
| Gill, MJ; Mah Ming, JB | 1 |
| Aberg, JA; Alston, BL; Brobst, SW; Fichtenbaum, CJ; Gerber, JG; Rosenkranz, SL; Segal, Y; Vega, JM; Yang, A | 1 |
| Blanco, J; Clotet, B; Moltó, J; Negredo, E; Pérez-Alvarez, N; Puig, J; Rey-Joly, C; Romeu, J; Ruiz, L | 1 |
| Deig, E; Guelar, A; Guil, J; Pedrol, E; Rodríguez-Martín, M; Soler, A | 1 |
| Palacios Muñoz, R; Santos González, J | 1 |
| Bennett, MT; Bondy, GP; Johns, KW | 1 |
| Gaughan, JP; Klibanov, OM; Tedaldi, EM; van den Berg-Wolf, M | 1 |
| Martín, T; Murillas, J; Portero, JL; Ramos, A | 1 |
| Currier, JS | 1 |
| Castro, JG; Gutierrez, L | 1 |
3 review(s) available for atorvastatin and HIV Coinfection
| Article | Year |
|---|---|
A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndrome; Pravastatin; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin | 2023 |
Statins to improve cardiovascular outcomes in treated HIV infection.
Topics: Atorvastatin; Carotid Intima-Media Thickness; Coronary Disease; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Practice Guidelines as Topic; Practice Patterns, Physicians'; Precision Medicine; Primary Prevention; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Treatment Outcome; United States | 2016 |
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrroles; Rosuvastatin Calcium; Simvastatin | 2016 |
18 trial(s) available for atorvastatin and HIV Coinfection
| Article | Year |
|---|---|
Evaluating the effect of atorvastatin exposure and vitamin D levels on lipid outcomes in people with HIV-1 with suppressed HIV-1 RNA and LDL cholesterol <130 mg/dL.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Treatment Outcome; Vitamin D | 2023 |
An open label randomized controlled trial of atorvastatin versus aspirin in elite controllers and antiretroviral-treated people with HIV.
Topics: Anti-Retroviral Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Viral Load | 2023 |
Effect of atorvastatin on subclinical atherosclerosis in virally-suppressed HIV-infected patients with CMV seropositivity: a randomized double-blind placebo-controlled trial.
Topics: Atherosclerosis; Atorvastatin; Carotid Intima-Media Thickness; Cholesterol, LDL; Cytomegalovirus Infections; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2021 |
A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV.
Topics: Adult; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Immunosenescence; Inflammation; Lymphocyte Activation; Male; Middle Aged; Pilot Projects; Raltegravir Potassium | 2020 |
The Effect of Atorvastatin + Aspirin on the Endothelial Function Differs with Age in Patients with HIV: A Case-Control Study.
Topics: Aspirin; Atorvastatin; Brachial Artery; Carotid Arteries; Carotid Intima-Media Thickness; Case-Control Studies; Endothelium, Vascular; HIV Infections; Humans; Risk Factors; Ultrasonography; Vasodilation | 2021 |
Novel mediators of statin effects on plaque in HIV: a proteomics approach.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Placebos; Proteome; Proteomics; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV.
Topics: Adolescent; Adult; Amino Acids; Atorvastatin; Biomarkers; Blood Proteins; Coronary Artery Disease; Double-Blind Method; Female; Fibrosis; Galectin 3; Galectins; Growth Differentiation Factor 15; HIV; HIV Infections; Humans; Inflammation; Interleukin-1 Receptor-Like 1 Protein; Interleukin-6; Lipoproteins, LDL; Male; Middle Aged; Receptors, Interleukin-1; Young Adult | 2018 |
Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.
Topics: Adult; Anti-HIV Agents; Atorvastatin; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocyte Activation; Lymphocyte Depletion; Male; Middle Aged; Pyrroles; Uganda; Viral Load | 2015 |
Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Amino Acids; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Treatment Outcome | 2015 |
Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Female; HIV Infections; Humans; Lipoproteins, LDL; Male; Middle Aged; Placebos; Serum; Treatment Outcome | 2016 |
Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atorvastatin; Cholesterol; Female; HIV Infections; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lopinavir; Male; Middle Aged; Ritonavir | 2016 |
Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.
Topics: Adolescent; Adult; Anti-HIV Agents; Atorvastatin; C-Reactive Protein; Child; Female; HIV Infections; Humans; Hyperlipidemias; Male; Young Adult | 2017 |
Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study.
Topics: Adult; Anti-HIV Agents; Atorvastatin; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Heptanoic Acids; HIV Infections; HIV-1; Humans; Male; Neopterin; Pilot Projects; Pyrroles; Viral Load | 2008 |
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial.
Topics: Adult; Atorvastatin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Over Studies; Double-Blind Method; Heptanoic Acids; HIV Infections; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Placebos; Pyrroles; RNA, Viral | 2011 |
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atorvastatin; Benzoxazines; Cholesterol, LDL; Cyclopropanes; Drug Interactions; Female; Heptanoic Acids; HIV Infections; HIV Seronegativity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Oxazines; Pravastatin; Pyrroles; Simvastatin | 2005 |
The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy.
Topics: Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Heptanoic Acids; HIV Infections; HIV-1; Humans; Pilot Projects; Pyrroles; RNA, Viral; Virus Replication | 2006 |
[Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia].
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atorvastatin; Female; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles | 2006 |
23 other study(ies) available for atorvastatin and HIV Coinfection
| Article | Year |
|---|---|
Inhibiting the HIV integration process: past, present, and the future.
Topics: Allosteric Regulation; Animals; Catalytic Domain; Drug Resistance, Viral; Enzyme Activators; Genetic Therapy; HIV; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Models, Molecular; Protein Conformation; Protein Multimerization; Virus Integration | 2014 |
Statin treatment prevents the development of pulmonary arterial hypertension in a nonhuman primate model of HIV-associated PAH.
Topics: Animals; Atorvastatin; Disease Models, Animal; HIV; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macaca mulatta; Macrophages, Alveolar; Monocytes; Pulmonary Arterial Hypertension; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Viral Load | 2019 |
Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Darunavir; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rosuvastatin Calcium; Treatment Outcome | 2020 |
Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV.
Topics: Aged; Aging; Atorvastatin; Drug Interactions; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged | 2020 |
Prescription of statins and pharmacokinetic interactions in Colombian patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Colombia; Cross-Sectional Studies; Databases, Factual; Drug Interactions; Endocrine System Diseases; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Risk Factors; Sex Factors; Young Adult | 2021 |
UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
Topics: Amlodipine; Anti-HIV Agents; Atorvastatin; Chromatography, High Pressure Liquid; Drug Interactions; HIV Infections; Humans; Linear Models; Metoprolol; Pravastatin; Reproducibility of Results; Rosuvastatin Calcium; Sensitivity and Specificity; Tandem Mass Spectrometry | 2019 |
Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care.
Topics: Adult; Alabama; Atorvastatin; California; CD4-Positive T-Lymphocytes; Cohort Studies; Comparative Effectiveness Research; Drug Interactions; Female; Fenofibrate; Fish Oils; Gemfibrozil; Heptanoic Acids; HIV Infections; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; North Carolina; Practice Guidelines as Topic; Pyrroles; Retrospective Studies; San Francisco; Treatment Outcome; Triglycerides; Washington | 2013 |
[Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients?].
Topics: Antiretroviral Therapy, Highly Active; Atorvastatin; Chemical and Drug Induced Liver Injury; Comorbidity; Contraindications; Cost-Benefit Analysis; Cytochrome P-450 CYP3A Inhibitors; Drug Substitution; Drug Synergism; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubular Necrosis, Acute; Middle Aged; Rhabdomyolysis; Ritonavir; Simvastatin | 2014 |
Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.
Topics: Anti-Retroviral Agents; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; HIV Infections; HIV-1; Humans; Immunologic Factors; Interferon-gamma; Lymphocyte Activation; Pravastatin; Pyrroles; Retrospective Studies; T-Lymphocyte Subsets; T-Lymphocytes | 2014 |
Should everyone ageing with HIV take a statin?
Topics: Amino Acids; Atherosclerosis; Atorvastatin; Coronary Vessels; Female; HIV Infections; Humans; Male | 2015 |
Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients.
Topics: Adult; Aged; Anti-Retroviral Agents; Atorvastatin; Cardiovascular Diseases; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Retrospective Studies; Rosuvastatin Calcium; Vitamin D Deficiency | 2017 |
Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Cohort Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Serum; Sulfonamides | 2011 |
Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load.
Topics: ADP-ribosyl Cyclase 1; Atorvastatin; CD4-Positive T-Lymphocytes; Down-Regulation; Female; Heptanoic Acids; HIV Infections; Humans; Lymphocyte Activation; Male; Membrane Glycoproteins; Pyrroles; Viral Load | 2011 |
Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Female; Heptanoic Acids; HIV Infections; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2002 |
Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV.
Topics: Adult; Anti-Bacterial Agents; Atorvastatin; Clarithromycin; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lopinavir; Male; Pyrimidinones; Pyrroles; Rhabdomyolysis; Ritonavir | 2003 |
[HIV infection: from Pneumocystis to statins].
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pneumocystis Infections; Pyrroles; Risk Factors | 2006 |
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Topics: Adult; Aged; Anti-Retroviral Agents; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Protease Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2007 |
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients.
Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Azetidines; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Ritonavir; Treatment Outcome | 2008 |
Atorvastatin for protease inhibitor-related hyperlipidaemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Male; Pyrroles; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1999 |
How to manage metabolic complications of HIV therapy: what to do while we wait for answers.
Topics: Anabolic Agents; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Exercise Therapy; Gemfibrozil; Growth Hormone; Guidelines as Topic; Heptanoic Acids; HIV Infections; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipodystrophy; Metabolic Diseases; Metformin; Nucleosides; Protease Inhibitors; Pyrroles; Reverse Transcriptase Inhibitors; Risk Factors; Thiazoles; Thiazolidinediones | 2000 |
ICAAC: nelfinavir interacts with statins and an antiseizure drug.
Topics: Anticholesteremic Agents; Anticonvulsants; Atorvastatin; Drug Interactions; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nelfinavir; Phenytoin; Pyrroles; Simvastatin | 2000 |
. . . from the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Topics: Anti-HIV Agents; Anti-Infective Agents; Antineoplastic Agents; Atorvastatin; Drug Administration Schedule; Drug Interactions; Drug Resistance, Microbial; Heptanoic Acids; HIV Infections; Humans; Pyrroles; Rhabdomyolysis | 2000 |
Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine.
Topics: Acute Kidney Injury; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Delavirdine; Drug Interactions; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Mixed Function Oxygenases; Pyrroles; Rhabdomyolysis | 2002 |